Literature DB >> 29045541

From hepatitis C virus infection to B-cell lymphoma.

L Couronné1,2,3, E Bachy4,5, S Roulland6, B Nadel6, F Davi7,8,9, M Armand7,8,9, D Canioni10, J M Michot11, C Visco12, L Arcaini13,14, C Besson15,16,17, O Hermine1,2,3.   

Abstract

In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL), especially marginal zone lymphoma, de novo or transformed diffuse large B-cell lymphoma and to a lesser extent, follicular lymphoma. Epidemiological data and clinical observations argue for an association between HCV and lymphoproliferative disorders. The causative role of HCV in NHL has been further supported by the response to antiviral therapy. Pathophysiological processes at stake leading from HCV infection to overt lymphoma still need to be further elucidated. Based on reported biological studies, several mechanisms of transformation seem however to emerge. A strong body of evidence supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to frank lymphoma, mostly of marginal zone subtype. By infecting lymphocytes, HCV could play a direct role in cellular transformation, particularly in de novo large B-cell lymphoma. Finally, HCV is associated with follicular lymphoma in a subset of patients. In this setting, it may be hypothesized that inflammatory cytokines stimulate proliferation and transformation of IgH-BCL2 clones that are increased during chronic HCV infection. Unraveling the pathogenesis of HCV-related B-cell lymphoproliferation is of prime importance to optimize therapeutic strategies, especially with the recent development of new direct-acting antiviral drugs.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  hepatitis C virus; models of transformation; non-Hodgkin lymphoma; oncogenesis

Mesh:

Substances:

Year:  2018        PMID: 29045541     DOI: 10.1093/annonc/mdx635

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

1.  Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

Authors:  Michele Merli; Marco Frigeni; Laurent Alric; Carlo Visco; Caroline Besson; Lara Mannelli; Alice Di Rocco; Angela Ferrari; Lucia Farina; Mario Pirisi; Francesco Piazza; Véronique Loustaud-Ratti; Annalisa Arcari; Dario Marino; Antonello Sica; Maria Goldaniga; Chiara Rusconi; Massimo Gentile; Emanuele Cencini; Francesco Benanti; Maria Grazia Rumi; Virginia Valeria Ferretti; Paolo Grossi; Manuel Gotti; Roberta Sciarra; Maria Chiara Tisi; Isabel Cano; Valentina Zuccaro; Francesco Passamonti; Luca Arcaini
Journal:  Oncologist       Date:  2018-12-14

2.  Lessons of the month 2: Ocular manifestations and complications of hepatitis C infection.

Authors:  Sarah Lw Fang; Livia Teo; Cheng Yi Loo; James W Li; Anindita Santosa
Journal:  Clin Med (Lond)       Date:  2021-07       Impact factor: 2.659

3.  Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?

Authors:  Ju Dong Yang; Gregory J Gores
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.425

Review 4.  Recent advances in understanding the biology of marginal zone lymphoma.

Authors:  Francesco Bertoni; Davide Rossi; Emanuele Zucca
Journal:  F1000Res       Date:  2018-03-28

Review 5.  Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip.

Authors:  Kaku Goto; Armando Andres Roca Suarez; Florian Wrensch; Thomas F Baumert; Joachim Lupberger
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

6.  Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort.

Authors:  Hyo Geun Choi; James L Zehnder; Young Kyung Lee; Hyun Lim; Miyoung Kim
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

7.  Cryoglobulinemic glomerulonephritis with underlying occult HBV infection and Waldenström macroglobulinemia: A case report.

Authors:  Yu-Che Chuang; Ying-Ren Chen; Te-Hui Kuo
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

8.  Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.

Authors:  Yung-Rung Lai; Ya-Lan Chang; Chiu-Hsiang Lee; Tung-Han Tsai; Kuang-Hua Huang; Chien-Ying Lee
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

9.  Extranodal Diffuse Large B-Cell Lymphoma of Bone and Soft Tissue Presenting With Marked Lymphedema and Hypercalcemia.

Authors:  Arafat Shabbir; Arsenije Kojadinovic; Sanaz Gidfar; Prabhjot S Mundi
Journal:  Cureus       Date:  2022-02-08

10.  Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals.

Authors:  George N Ioannou; Pamela K Green; Kristin Berry; Solomon A Graf
Journal:  Hepatol Commun       Date:  2019-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.